Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

298.37
+3.371.14%
Volume:33.26K
Turnover:9.95M
Market Cap:5.95B
PE:30.73
High:301.96
Open:294.79
Low:294.32
Close:295.00
52wk High:326.63
52wk Low:175.89
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.36
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:6.15
PE(LYR):48.67

Loading ...

Ligand Pharmaceuticals Bets Big on Royalty Growth

TIPRANKS
·
May 20

Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After Its 97% One-Year Surge?

Simply Wall St.
·
May 19

XOMA Royalty amends merger agreement with Ligand Pharmaceuticals

TIPRANKS
·
May 18

Ligand amends XOMA Royalty merger agreement to add new holding company entity

Reuters
·
May 18

Ligand director John W. Kozarich sells USD 572,598 common shares

Reuters
·
May 15

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
May 12

Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push

TIPRANKS
·
May 12

Ligand Q1 FY26 operating income swings to USD 17.4 million; revenue rises 14% to USD 51.7 million

Reuters
·
May 09

Stock Track | Ligand Pharmaceuticals Soars 5.80% Intraday Following RBC Capital Price Target Hike

Stock Track
·
May 09

Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 09

RBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)

TIPRANKS
·
May 08

Ligand Pharmaceuticals Down Over 9%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk

Dow Jones
·
May 08

Stock Track | Ligand Pharmaceuticals Plunges 7.33% in Pre-Market After Q1 Earnings and Sales Miss Estimates

Stock Track
·
May 07

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $8.50 to $9.50, vs. FactSet Est of $8.99

MT Newswires Live
·
May 07

Ligand Q1 revenue rises 14% on royalty growth

Reuters
·
May 07

Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate

Benzinga Earnings
·
May 07

BRIEF-Ligand Pharmaceuticals Q1 EPS USD -0.67

Reuters
·
May 07

Ligand Pharmaceuticals Outlook FY Revenue USD 270-310 Million

THOMSON REUTERS
·
May 07

Orchestra BioMed receives $15M payment from Ligand

TIPRANKS
·
May 07

Ligand CLO Andrew Reardon disposes of common shares worth $1,155,172.85

Reuters
·
May 05